New York, June 3, 2026, 08:04 (EDT)
Verrica Pharmaceuticals Inc. was last quoted at $5.79 before Wednesday’s regular U.S. session, after the Nasdaq-listed dermatology drugmaker closed Tuesday at $5.80, down 2.2%. The stock is heading into a June 4 investor presentation with traders weighing YCANTH sales growth against a thin cash runway.
U.S. cash trading had not yet opened. Nasdaq’s regular session runs from 9:30 a.m. to 4:00 p.m. Eastern time, while premarket trading — orders placed before the main session, often with lighter volume — runs from 4:00 a.m. to 9:30 a.m.; June 3 is not listed as a 2026 market holiday.
That matters now because Verrica’s next public test is not a quarterly report. Chief Executive Jayson Rieger is due to present at the Jefferies Global Healthcare Conference in New York on Thursday at 11:05 a.m. ET, during a meeting running June 2-4 for healthcare companies and investors.
The news tape is thin. Verrica’s website lists the May 28 Jefferies notice as its latest release, following a May 12 first-quarter report, leaving the stock without a fresh company filing or product update in the past 48 hours.
In that May update, Rieger said the quarter showed “accelerating growth in market demand for YCANTH” and said Verrica was “beginning to realize the traction” from steps taken last year. The company reported first-quarter revenue of $5.0 million, including $4.3 million of U.S. YCANTH net product revenue, up 25.4% from a year earlier, while its net loss was $9.7 million. GlobeNewswire
YCANTH is Verrica’s approved treatment for molluscum contagiosum, a contagious viral skin infection mainly affecting children. The company is also testing YCANTH for common warts in Phase 3, meaning late-stage human trials, and is developing VP-315 for basal cell carcinoma, a common skin cancer.
Analyst support has not disappeared. H.C. Wainwright analyst Raghuram Selvaraju assumed coverage of Verrica on May 26 with a Buy rating and a $12 price target, more than double Tuesday’s close, according to a market report. A Buy rating is an analyst’s view that a stock should outperform, not a guarantee.
The broader tape was not the obvious drag. Major U.S. indexes rose Tuesday, with the S&P 500 setting another high and the Nasdaq Composite posting a modest gain, the Associated Press reported.
Competitive pressure is more about dermatology sales access than a direct molluscum rival. Arcutis Biotherapeutics markets ZORYVE for eczema, seborrheic dermatitis and plaque psoriasis, while Organon’s VTAMA is approved for plaque psoriasis and atopic dermatitis; both compete for attention from dermatology prescribers and payers, even outside Verrica’s lead niche.
But the downside case is clear. Verrica’s 10-Q said it had $20.6 million of cash as of March 31, used $9.2 million in operating cash in the quarter and concluded “substantial doubt” existed about its ability to continue as a going concern within one year, accounting language meaning the company sees serious doubt about operating without more funding or other relief. SEC
The week-ahead question is whether Rieger can give investors enough detail on YCANTH demand, Japan partner Torii Pharmaceutical and the common-warts trial timetable to offset that funding concern. Without that, the stock may keep trading less like a product-growth story and more like a small-cap biotech balance-sheet story.
